PriceTargets.com logo

agilon health - AGL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.81
  • Forecasted Upside: 217.58%
  • Number of Analysts: 20
  • Breakdown:
  • 3 Sell Ratings
  • 13 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.46 As of 10/30/2024 03:52 PM ET
▼ -0.06 (-2.38%)

This chart shows the closing price for AGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New agilon health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGL

Analyst Price Target is $7.81
▲ +217.58% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for agilon health in the last 3 months. The average price target is $7.81, with a high forecast of $18.00 and a low forecast of $2.50. The average price target represents a 217.58% upside from the last price of $2.46.

This chart shows the closing price for AGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 20 contributing investment analysts is to hold stock in agilon health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
5/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
8/6/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
5/2/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
7/31/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
9/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
10/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 13 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2024CitigroupReiterated RatingNeutral ➝ Sell$7.00 ➝ $2.50
10/8/2024Evercore ISILower TargetIn-Line ➝ In-Line$7.00 ➝ $4.00
10/2/2024Bank of AmericaDowngradeBuy ➝ Underperform$3.00
8/9/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$5.00 ➝ $4.00
8/8/2024BenchmarkReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
7/9/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$5.50 ➝ $7.00
5/30/2024Baird R WUpgradeHold
5/30/2024Robert W. BairdInitiated CoverageNeutral$6.00
5/24/2024Truist FinancialBoost TargetHold ➝ Hold$6.40 ➝ $6.50
5/1/2024Stifel NicolausLower TargetHold ➝ Hold$8.00 ➝ $7.00
4/22/2024CitigroupInitiated CoverageNeutral$6.00
3/6/2024BarclaysInitiated CoverageUnderweight$5.00
2/29/2024BenchmarkLower TargetBuy ➝ Buy$13.00 ➝ $9.00
2/29/2024Truist FinancialLower TargetHold ➝ Hold$10.00 ➝ $7.50
2/28/2024Evercore ISILower TargetIn-Line ➝ In-Line$7.00 ➝ $6.00
2/28/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$11.00 ➝ $8.00
2/26/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$25.00 ➝ $6.50
2/26/2024TD CowenDowngradeOutperform ➝ Market Perform$12.00 ➝ $6.50
2/22/2024Stifel NicolausLower TargetHold ➝ Hold$10.00 ➝ $9.00
1/8/2024Leerink PartnrsDowngradeOutperform ➝ Market Perform
1/8/2024Leerink PartnersDowngradeOutperform ➝ Market Perform
1/8/2024Stifel NicolausDowngradeBuy ➝ Hold
1/8/2024Wolfe ResearchDowngradeOutperform ➝ Peer Perform
1/5/2024Truist FinancialDowngradeBuy ➝ Hold$23.00 ➝ $10.00
1/5/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$17.00 ➝ $9.00
12/11/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$14.00
12/6/2023JMP SecuritiesInitiated CoverageMarket Outperform$18.00
11/21/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$27.00 ➝ $12.00
11/15/2023BenchmarkLower TargetBuy ➝ Buy$28.00 ➝ $22.00
11/13/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$23.00 ➝ $16.00
11/9/2023Truist FinancialLower TargetBuy ➝ Buy$27.00 ➝ $23.00
11/9/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$25.00 ➝ $22.00
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$28.00 ➝ $23.00
10/20/2023BenchmarkInitiated CoverageBuy$28.00
10/11/2023Evercore ISILower Target$21.00 ➝ $20.00
8/15/2023TD CowenLower TargetOutperform ➝ Outperform$29.00 ➝ $25.00
8/15/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$29.00 ➝ $25.00
6/20/2023Truist FinancialLower Target$35.00 ➝ $27.00
6/13/2023Evercore ISIInitiated CoverageInline$22.50
5/15/2023Deutsche Bank AktiengesellschaftLower Target$28.00 ➝ $27.00
5/10/2023Stifel NicolausBoost Target$29.00 ➝ $32.00
4/17/2023Truist FinancialBoost TargetBuy$29.00 ➝ $35.00
3/16/2023Wells Fargo & CompanyBoost Target$22.00 ➝ $28.00
3/6/2023GuggenheimBoost TargetBuy$21.00 ➝ $30.00
3/3/2023Deutsche Bank AktiengesellschaftBoost Target$26.00 ➝ $28.00
12/8/2022Stifel NicolausInitiated CoverageBuy$23.00
11/15/2022The Goldman Sachs GroupLower TargetBuy$38.00 ➝ $34.00
11/15/2022Wells Fargo & CompanyLower TargetOverweight$28.00 ➝ $22.00
11/4/2022Leerink PartnersLower TargetOutperform$33.00 ➝ $30.00
9/14/2022Royal Bank of CanadaInitiated CoverageOutperform$33.00
9/12/2022The Goldman Sachs GroupInitiated CoverageBuy$38.00
9/7/2022Truist FinancialLower TargetBuy$33.00 ➝ $29.00
8/8/2022Wells Fargo & CompanyBoost TargetOverweight$23.00 ➝ $28.00
7/14/2022Truist FinancialBoost TargetBuy$30.00 ➝ $33.00
6/24/2022BTIG ResearchInitiated CoverageNeutral
5/10/2022Deutsche Bank AktiengesellschaftLower Target$30.00 ➝ $26.00
5/10/2022GuggenheimLower Target$32.00 ➝ $30.00
3/31/2022Leerink PartnersBoost TargetOutperform$25.00 ➝ $33.00
3/29/2022GuggenheimInitiated CoverageBuy$32.00
3/15/2022Leerink PartnersLower TargetOutperform$35.00 ➝ $25.00
1/25/2022Deutsche Bank AktiengesellschaftLower Target$30.00 ➝ $29.00
12/14/2021Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$36.00 ➝ $30.00
11/3/2021Deutsche Bank AktiengesellschaftLower TargetBuy$44.00 ➝ $36.00
11/1/2021Leerink PartnersLower TargetOutperform$37.00 ➝ $35.00
10/20/2021Jefferies Financial GroupInitiated CoverageBuy$35.00
10/13/2021Truist FinancialLower TargetBuy$41.00 ➝ $35.00
9/27/2021Leerink PartnersInitiated CoverageOutperform$37.00
9/9/2021CowenInitiated CoverageOutperform$44.00
6/3/2021Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $44.00
5/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$42.00 ➝ $45.00
5/10/2021William BlairInitiated CoverageOutperform
5/10/2021Wolfe ResearchInitiated CoverageOutperform$37.00
5/10/2021Truist FinancialInitiated CoverageBuy$40.00
5/10/2021JPMorgan Chase & Co.Initiated CoverageOverweight$42.00
5/10/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$42.00
5/10/2021Bank of AmericaInitiated CoverageBuy$41.00
5/10/2021The Goldman Sachs GroupInitiated CoverageBuy$42.00
5/10/2021Wells Fargo & CompanyInitiated CoverageOverweight$38.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 42 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2024
  • 3 very positive mentions
  • 45 positive mentions
  • 3 negative mentions
  • 8 very negative mentions
Mentions as of
5/3/2024
  • 6 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 7 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

agilon health logo
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Read More

Today's Range

Now: $2.46
Low: $2.36
High: $2.50

50 Day Range

MA: $3.54
Low: $2.52
High: $4.59

52 Week Range

Now: $2.46
Low: $2.36
High: $18.37

Volume

2,483,021 shs

Average Volume

4,899,426 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of agilon health?

The following Wall Street research analysts have issued reports on agilon health in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, Benchmark Co., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for AGL.

What is the current price target for agilon health?

16 Wall Street analysts have set twelve-month price targets for agilon health in the last year. Their average twelve-month price target is $7.81, suggesting a possible upside of 228.3%. JMP Securities has the highest price target set, predicting AGL will reach $18.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $2.50 for agilon health in the next year.
View the latest price targets for AGL.

What is the current consensus analyst rating for agilon health?

agilon health currently has 3 sell ratings, 13 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AGL, but not buy more shares or sell existing shares.
View the latest ratings for AGL.

What other companies compete with agilon health?

Other companies that are similar to agilon health include Progyny, Premier, Bright Health Group, Surgery Partners and BrightSpring Health Services. Learn More about companies similar to agilon health.

How do I contact agilon health's investor relations team?

The company's listed phone number is 562-256-3800 and its investor relations email address is [email protected]. The official website for agilon health is agilonhealth.com. Learn More about contacing agilon health investor relations.